(177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior (223)Ra (RALU Study)

(223)Ra-dichloride ((223)Ra) and (177)Lu-prostate-specific membrane antigen (PSMA) are approved treatments for metastatic castration-resistant prostate cancer (mCRPC). The safety and effectiveness of sequential use of (223)Ra and (177)Lu-PSMA in patients with mCRPC are not well described. This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahbar, Kambiz, Essler, Markus, Eiber, Matthias, la Fougère, Christian, Prasad, Vikas, Fendler, Wolfgang P., Rassek, Philipp, Hasa, Ergela, Dittmann, Helmut, Bundschuh, Ralph A., Pabst, Kim M., Kurtinecz, Milena, Schmall, Anja, Verholen, Frank, Sartor, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2023
Materias:
Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690117/
https://www.ncbi.nlm.nih.gov/pubmed/37827838
http://dx.doi.org/10.2967/jnumed.123.266125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690117/
https://www.ncbi.nlm.nih.gov/pubmed/37827838
http://dx.doi.org/10.2967/jnumed.123.266125

Ejemplares similares